All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics Inc. have agreed to jointly develop and commercialize Takeda's TAK-935 in rare pediatric epilepsies, splitting costs and potential profits 50-50.
